Citizens Jmp Forecasts Strong Price Appreciation for Iovance Biotherapeutics (NASDAQ:IOVA) Stock

Iovance Biotherapeutics (NASDAQ:IOVA) had its target price increased by equities research analysts at Citizens Jmp from $8.00 to $12.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the biotechnology company’s stock. Citizens Jmp‘s price target indicates a potential upside of 50.68% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. TD Cowen upped their target price on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, August 24th. Robert W. Baird lifted their price target on Iovance Biotherapeutics from $6.00 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. Barclays boosted their price target on Iovance Biotherapeutics from $15.00 to $18.00 and gave the stock an “overweight” rating in a report on Tuesday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Tuesday, September 29th. Finally, Mizuho upped their price objective on Iovance Biotherapeutics from $10.00 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.70.

Iovance Biotherapeutics Trading Up 2.9%

IOVA stock traded up $0.22 during mid-day trading on Friday, hitting $7.96. 1,767,961 shares of the company were exchanged, compared to its average volume of 15,777,470. The business has a 50 day simple moving average of $11.38 and a 200-day simple moving average of $5.94. The stock has a market capitalization of $3.61 billion, a PE ratio of -10.77 and a beta of 0.88. Iovance Biotherapeutics has a 1-year low of $2.08 and a 1-year high of $15.37.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business had revenue of $121.47 million for the quarter, compared to the consensus estimate of $115.98 million. Iovance Biotherapeutics’s revenue for the quarter was up 64.8% compared to the same quarter last year. Equities research analysts expect that Iovance Biotherapeutics will post -0.45 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Brighton Jones LLC increased its stake in shares of Iovance Biotherapeutics by 5.1% in the 3rd quarter. Brighton Jones LLC now owns 40,069 shares of the biotechnology company’s stock valued at $594,000 after acquiring an additional 1,954 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Iovance Biotherapeutics by 867.6% during the 3rd quarter. Pictet Asset Management Holding SA now owns 416,539 shares of the biotechnology company’s stock valued at $6,043,000 after acquiring an additional 373,491 shares during the period. Kestra Advisory Services LLC lifted its position in shares of Iovance Biotherapeutics by 25.2% during the 3rd quarter. Kestra Advisory Services LLC now owns 42,150 shares of the biotechnology company’s stock valued at $625,000 after acquiring an additional 8,483 shares during the period. Pathway Financial Advisers LLC bought a new position in Iovance Biotherapeutics during the third quarter worth $427,000. Finally, Compass Financial Management LLC bought a new position in Iovance Biotherapeutics during the third quarter worth $37,000. 77.03% of the stock is owned by institutional investors and hedge funds.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Q3 results topped expectations. Iovance reported about $122 million in revenue, a record, and a loss of $0.05 per share versus the $0.09 loss analysts expected. Amtagvi sales drove growth, gross margin rose to about 60%, and lower R&D costs helped improve results. The company reaffirmed its 2026 revenue outlook. Article: IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs
• Positive Sentiment: Sarcoma program gained regulatory momentum. Lifileucel received FDA Fast Track designation following strong sarcoma trial data. Iovance also reported a 55.6% response rate in UPS and DDLPS, with a registrational trial underway. Article: Iovance Biotherapeutics Lifileucel Wins Fast Track After Strong Sarcoma Trial Data
• Neutral Sentiment: An analyst upgraded the stock to Buy after resetting expectations, citing momentum in the Amtagvi melanoma launch. The analyst also cautioned that the opportunity in lung cancer may have been overestimated. Article: Iovance: Reset Expectations Make The Stock a Buy Again
• Negative Sentiment: Lung-cancer data remain a risk. Lifileucel showed a 24.6% response rate across 69 evaluable non-squamous NSCLC patients, slightly below an earlier interim result. The reported 59.1% response rate in a biomarker-selected subgroup is more encouraging, but the treatment’s broader potential remains uncertain. Article: Iovance Reports Q3 2026 Results and Updates

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc (NASDAQ: IOVA) is a biotechnology company focused on developing and commercializing personalized cell therapies for patients with cancer. Its technology is based on tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded outside the body, and reinfused to help attack cancer cells.

The company’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved in the United States for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment.